Teva Pharmaceutical Industries Ltd. (TEVA) said that the U.S. Food and Drug Administration has granted final approval for the company's Abbreviated New Drug Application to market its generic version of Tap Pharmaceutical's proton pump inhibitor Prevacid or lansoprazole) Delayed-Release Capsules, 15 mg and 30 mg. The company said the customers would begin receiving product on November 11, 2009.
Teva Pharmaceutical Industries Ltd., headquartered in Israel, is a generic pharmaceutical company.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.